Trial Profile
A Phase 2 Trial of Florbetapir F18 PET Imaging of beta-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Cognition disorders; Parkinson's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 15 Oct 2014 New trial record